Grazax in children

Grazax, the grass-pollen allergen tablet from ALK-Abello, has had its licence extended to include use in children and adolescents aged five to 17 years.

The fast-melting sublingual tablet for once-daily administration is indicated for the treatment of grass pollen-induced rhinitis and conjunctivitis.

Grazax is non-injection immunotherapy and the first dose should be given under medical supervision.

View Grazax drug record

Further information: ALK-Abello

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases